tbuckley/cabot-search huggingface dataset:
AB0701 Comparison of the new acr/eular classification criteria of anca-associated vasculitis with the ema algorithm in classification of vasculitis
Authors: S. Li, Q. Zhang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> A new set of classification criteria for ANCA-associated vasculitis (AAV) was presented in 2017's ACR annual scientific meeting. In order to evaluate this new set of classification, we conducted the current study to compare it with the EMA's consensus algorithm for classification of systemic vasculitis proposed by Watt et al. in our centre. <h3>Methods</h3> One hundred and twenty-two Chinese patients with clinically diagnosed as AAV in our centre during the past 15 years were retrospectively studied. We compared the new set of ACR/EULAR's classification criteria for AAV, with the EMA's consensus algorithm with surrogate parameters, in the same cohort of patients with primary systemic vasculitis. <h3>Results</h3> Applying the EMA's consensus algorithm with surrogate parameters, the diagnoses were EGPA (n.3), GPA (n.55), microscopic polyangiitis (MPA) (n.47), drug related AAV (n.2), and unclassified (n.5). Using the new ACR/EULAR's classification criteria for AAV, the diagnoses were EGPA (n.8), GPA (n.33), MPA (n.65), overlap with EGPA and GPA (n.2), overlap with GPA and MPA (n.8), and unclassified (n.7) (See the below picture). <h3>Conclusions</h3> <sup>The new 2017</sup> ACR/EULAR classification criteria for AAV and Watts' algorithm were all useful methods to classify patients with systemic vasculitis. The Watts' algorithm can classify all patients into a single category, with more GPA patients, less unclassified patients and without overlapping diagnosis, in comparison, the new 2017 ACR/EULAR classification criteria classified more MPA patients, more unclassified and more overlapping patients. <h3>Disclosure of Interest</h3> None declared
Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Authors: Elise A. Chong, Jakub Svoboda, Sunita Dwivedy Nasta, Daniel J. Landsburg, Nicole Winchell, Ellen Napier, Anthony R. Mato, J. Joseph Melenhorst, Marco Ruella, Simon F Lacey, Carl H June, Stephen J. Schuster
Journal: Blood (2018)
Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection
Authors: Hye Won Lee, Seung Up Kim, Oidov Baatarkhuu, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim
Journal: Clinical Gastroenterology and Hepatology (2019)
Survival Benefit with Standard-Dose Decitabine Versus Standard-Dose Azacitidine in Patients with Lower-Risk Myelodysplastic Syndromes
Authors: Byung-Hyun Lee, Ka-Won Kang, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Hojoon Choi, Se Ryun Lee, Hwa Jung Sung, Yong Park, Chul Won Choi, Byung Soo Kim
Journal: Blood (2018)
AB1001 Management of glucocorticoid-induced osteoporosis in rheumatoid arthritis: the example of the “ric nord de france” cohort
Authors: J. Corli, G. Baudens, R.-M. Flipo, B. Cortet
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Glucocorticoid-induced osteoporosis (GIOP) is the most common cause of secondary osteoporosis. Patients followed for Rheumatoid Arthritis (RA) are particularly exposed to OP and have a greater risk of fracture, which must be prevented. The newest French guidelines for GIOP management were published in 2014 and it is not known yet how they are applied in real life. <h3>Objectives</h3> The objective of our study was to investigate the treatment of glucocorticoid-induced osteoporosis in the Rhumatismes Inflammatoires Chroniques – Nord de France (formerly known as RIC-NPC) network in 2016 for patients with rheumatoid arthritis (RA). <h3>Methods</h3> In this observational study, the patients studied were followed in the RIC network for RA from 2004 until June 2016, had at least one bone mineral density (BMD) assessment and glucocorticoid therapy during follow-up. Demographic characteristics of patients, BMD results, fractures and treatments implemented were collected from network data completed during consultations by practitioners. <h3>Results</h3> 647 patients were enrolled, including 511 women (79%). The average age of patients was 65.5 years (SD=12) with a mean DAS28 of 3.91 (SD=1.44), mean dose of steroid of 7.6 mg (SD=6.6) and a mean duration of treatment of 49 months (SD=53.7). The average T-score at the first BMD assessment was −0.99 at the spine and −1.03 at the total hip. 298 patients received an anti-osteoporotic treatment (46%). Treated patients were older (p&lt;0.0001), with lower weight (p=0.001) and had a lower T-score at both the spine and the total hip (p&lt;0.0001 for both sites). They most often underwent a prior fracture (p&lt;0.0001), and an initial T-score less than – 1.5 SD (p&lt;0.0001). <h3>Conclusions</h3> Our study has the advantage of reflecting the management of GIOP in a ”real life” cohort. Almost half of our patients followed for RA who received corticosteroids had received treatment. According to French guidelines the number of patients requiring an anti-osteoporotic treatment should be higher. <h3>References</h3> [1] Briot K, Cortet B, Roux C, et al. 2014update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine2014;81:493–501. [2] Kok C, Sambrook PN. Secondary osteoporosis in patients with an osteoporotic fracture. Best Pract Res Clin Rheumatol2009;23:769–79. [3] Wibaux C, Baudens G, Cortet B, et al. Évaluation de la prise en charge de l’ostéoporose cortico-induite chez les patientes du réseau RIC-Nord-Pas-de-Calais. Rev Rhum2007;74:1035. <h3>Disclosure of Interest</h3> J. Corli Grant/research support from: Amgen, G. Baudens Grant/research support from: Amgen, R.-M. Flipo: None declared, B. Cortet Grant/research support from: Amgen
Herpes zoster infection
Authors: Phuc Le, Michael Rothberg
Journal: BMJ (2019)

### What you need to know

Herpes zoster is caused by reactivation of a primary infection with varicella zoster virus.1 After a primary infection, the virus lies dormant in dorsal root or cranial nerve ganglia. Reactivation causes the typical dermatomal pain and vesicular rash (fig 1).



Fig 1 
Vesicular rash caused by herpes zoster



Varicella zoster (commonly known as chickenpox) and herpes zoster (commonly known as shingles) are caused by the same herpes virus. Varicella follows the initial infection and causes a generalised rash, whereas herpes zoster occurs after reactivation, years later, and symptoms are usually localised to a specific dermatome.

The overall annual incidence of herpes zoster in the UK is estimated to be 1.85-3.9 cases per 1000 population,2 increasing with age from fewer than two cases per 1000 among people under 50 to 11 cases per 1000 among people aged 80 or older. In the US, incidence ranges from 1.2 to 3.4 cases per 1000 person years, increasing with age to 3.9 to 11.8 cases per 1000 person years among people aged 65 or older.34

### Who is at risk?

Over 90% of adults in the US have serological evidence of primary varicella …
FRI0497 Clinical characteristics and treatment outcomes of patients with behÇet’s disease and vascular involvement
Authors: H. Kim, Y. Eun, I.Y. Kim, H. Jeong, E.-J. Park, J. Hwang, J.Y. Chai, J.K. Ahn, J. Lee, E.-M. Koh, D.-K. Kim, H.-S. Cha
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The international Chapel Hill Consensus Conference (CHCC) categorised Behçet's disease (BD) as variable vessel vasculitis, which was defined as vasculitis that can affect vessels of any size and type. Vascular manifestations have been reported in up to 50% of patients with BD, most commonly as venous thrombosis. <h3>Objectives</h3> The aim of this study is to investigate characteristics and treatment outcomes of patients with vascular BD, particularly with large vessel involvement. <h3>Methods</h3> A retrospective review was performed on 2496 patients with ICD-10 code of Behçet's disease and/or aortic disease who visited Samsung Medical Centre between 2004 and 2014. Patients who were suspected to have BD and vascular involvement were enrolled. <h3>Results</h3> Eighty-three patients with clinical features of BD and vascular involvement were identified. Although less than half satisfied the classic International Study Group (ISG) criteria, greater proportion fulfilled the International Criteria for BD (ICBD), and all of the patients satisfied at least "suspected BD" according to the Japanese criteria. Fifty patients had arterial lesions including 34 with aorta involvement. Another 33 patients had venous thrombosis without arterial lesions. Patients showed a male predominance (87%) and a predilection of young age with the median of 42 years old. The most prominent type of arterial lesions was aneurysm (80%) with a high frequency of pseudoaneurysms. Among the aorta, the thoracic aorta was most commonly involved and 18 patients had aortic valve regurgitation. Seventy-five (90%) patients received glucocorticoids with a median initial dose of prednisolone of 30 mg per day and 68 (82%) received immunosuppressive treatment. Half of the patients had more than one relapse after stabilisation of the first vascular event. During the course, 44 patients underwent surgery and/or endovascular treatment and 60% of these patients had repeated treatment for the relapse. These included 31 aortic valve replacements on 13 patients. <h3>Conclusions</h3> Patients with vascular BD showed a predilection of young male and 60% of patients had arterial involvement. The aorta was affected in more than half of the patients who had arterial involvement. Aneurysmal change was frequent finding and relapse rate was high during disease course. Further studies into a practical and specialised diagnostic tool for vascular BD and optimal treatment strategies are required. <h3>Disclosure of Interest</h3> None declared
High Molecular Remission Rate in Pediatric Patients (pts) with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (r/r ALL) Treated with Blinatumomab: Rialto an Open-Label, Multicenter, Expanded Access Study
Authors: Franco Locatelli, Gerhard Zugmaier, Peter Bader, Sima Jeha, Paul-Gerhardt Schlegel, Jean-Pierre Bourquin, Rupert Handgretinger, Benoit Brethon, Claudia Rossig, Christiane Chen-Santel
Journal: Blood (2018)
Use of Caenorhabditis elegans as a model for studying MGMT's role in DNA transactions
Authors: Nathan I. Bailey, Afzal A. Siddiqui, Kalkunte S. Srivenugopal
Journal: Cancer Research (2006)

274  Our laboratory has recently discovered that human 06-methylguanine DNA methyltransferase (MGMT), a unique DNA repair protein and an anticancer target, interacts with replication components (e.g. PCNA), and is also an integral part of the replication licensing system (ORCs/Cdt1/geminin etc.) that ensures no part of the genome is replicated more than once in the S phase. The free living nematode, Caenorhabditis elegans offers an elegant system to study MGMT9s role in licensing control, and how it interfaces with differentiation and developmental programs at an organism level. C. elegans has two distinct orthologues of MGMT, known as AGT-1 and AGT-2, about which little is known. To this end, we first established an RNAi protocol to deplete either gene and compared the F1 progeny against wild type for differences in DNA synthesis and embryo development. Second, using O6-benzylguanine, a specific inhibitor of the AGT proteins, we established an embryo counting assay to determine brood size of the worms. Finally, using microscopic techniques (phase contrast and immunofluorescence), we have shown that AGT depletion causes gross morphological changes in the worm. Our preliminary data suggests that both AGT genes play a role in embryogenesis and germ line differentiation, and that loss of either gene results in fewer embryos in the fertile adult worms. Our other studies have shown that MGMT inactivation inhibits DNA synthesis and MGMT overexpression in human tumor cells induces polyploidy. Ongoing experiments to elucidate MGMT9s role in replication licensing of chromosomal DNA will be described (Supported by RO1 CA 97343 grant to KSS and the Mirick-Myers Endowment in Geriatric Medicine of TTUHSC, Amarillo ).
David John Weatherall: haematologist and geneticist whose work on thalassaemia showed the potential of molecular medicine
Authors: Tom Solomon
Journal: BMJ (2019)

Credit: Tom Solomon

David Weatherall was an icon of British medicine, a pioneering haematologist and geneticist whose work on thalassaemia showed the potential of applying molecular approaches to clinical medicine and led to the concept of clinician-scientist, as we know it today.

Born in Liverpool, Weatherall, as a student, was inspired by clinicians at the forefront of their specialism, including Rod Gregory, the discoverer of gastrin; and Harry Sheehan of the eponymous syndrome. He became interested in genetics while working as house physician to Cyril Clarke, who studied butterfly genetics as a hobby and would later identify the cause of rhesus haemolytic disease. A visit by the great geneticist JBS Haldane also inspired Weatherall.

Although Clarke and Haldane may have sparked Weatherall’s interest in genetics, it was a fortuitous encounter with a patient in Singapore that would set him on his way. After medical school and house jobs, Weatherall signed up for national service, but because of a “fear of flying, snakes, and bullets” asked to remain in the UK. As he delighted in telling people, however, through the army’s incompetence he was promptly despatched to Singapore, where he was in put in charge of the children’s ward despite having no paediatric experience. One of his first patients was the daughter of a Gurkha. She was severely anaemic and needed regular blood transfusions, but no cause could be found. Working with a local biochemist, Weatherall showed that she had thalassaemia, …
Effective Self-Management for Early Career Researchers in the Natural and Life Sciences
Authors: Natalia Z. Bielczyk, Ayaka Ando, AmanPreet Badhwar, Chiara Caldinelli, Mengxia Gao, Amelie Haugg, Leanna M. Hernandez, Kaori L. Ito, Dan Kessler, Dan Lurie, Meena M. Makary, Aki Nikolaidis, Michele Veldsman, Christopher Allen, Adriana Bankston, Katherine L. Bottenhorn, Ricarda Braukmann, Vince Calhoun, Veronika Cheplygina, Catarina Costa Boffino, Ece Ercan, Karolina Finc, Heidi Foo, Ali Khatibi, Christian La, David M.A. Mehler, Sridar Narayanan, Russell A. Poldrack, Pradeep Reddy Raamana, Taylor Salo, Claire Godard-Sebillotte, Lucina Q. Uddin, Davide Valeriani, Sofie L. Valk, Courtney C. Walton, Phillip G.D. Ward, Julio A. Yanes, Xinqi Zhou
Journal: Neuron (2020)
Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)
Authors: Susanne Isfort, Frank Stegelmann, Martine Klausmann, Holger Schulz, Wiebke Hollburg, Haifa Kathrin Al-Ali, Joachim R. Goethert, Florian H. Heidel, Christoph Maintz, Mathias Haenel, Uwe Platzbecker, Richard Hansen, Andras Keszei, Judith Gecht, Kim Kricheldorf, Andrea Kaifie, Martina Crysandt, Deniz Gezer, Martin Griesshammer, Tim H Brümmendorf, Konstanze Döhner, Steffen Koschmieder
Journal: Blood (2018)
Patient-reported outcome measures in the recovery of adults hospitalised with community-acquired pneumonia: a systematic review
Authors: Harry J. Pick, Charlotte E. Bolton, Wei Shen Lim, Tricia M. McKeever
Journal: European Respiratory Journal (2019)

Symptomatic and functional recovery are important patient-reported outcome measures (PROMs) in community-acquired pneumonia (CAP) that are increasingly used as trial end-points. This systematic review summarises the literature on PROMs in CAP.Comprehensive searches in accordance with the PRISMA statement were conducted to March 2017. Eligible studies included adults discharged from hospital following confirmed CAP and reporting PROMs.15 studies (n=5644 patients) were included; most were of moderate quality. Studies used a wide range of PROMs and assessment tools. At 4-6 weeks post-discharge, the commonest symptom reported was fatigue (45.0-72.6% of patients, three studies), followed by cough (35.3-69.7%) and dyspnoea (34.2-67.1%); corresponding values from studies restricted by age <65 years (two studies) were lower: fatigue 12.1-25.7%, cough 19.9-31.9% and dyspnoea 16.8-27.5%. Functional impairment 4 weeks post-discharge was reported in 18-51% of patients (two studies), while median time to return to normal activities was between 15 and 28 days (three studies).Substantial morbidity is reported by patients up to 6 weeks post-discharge. There is weak methodological consistency across existing studies. A core set of PROMs for use in future studies is suggested.
Abstract 19944: The Impact of Over-Sizing Transcathter Heart Valve Deployment for Silent Cerebral Infarction After Transfemoral Aortic Valve Replacement
Authors: Keiko Kajio, Kazuki Mizutani, Masahiko Hara, Tsukasa Okai, Shinsuke Nishimura, Asahiro Ito, Shinichi Iwata, Takashi Murakami, Toshihiko Shibata, Minoru Yoshiyama
Journal: Circulation (2017)

Introduction: The incidence of symptomatic cerebral infarction after transcatheter aortic valve replacement (TAVR) ranges from 2.0% to 5.0%. Furthermore, the incidence of silent cerebral infarction (SCI) detected by diffusion-weighted magnetic resonance imaging (DW-MRI) exceeds 50%, and it has been reported that SCI might relate long-term cognitive impairment. However, there has not been one point of view as predictors for SCI after TAVR. Therefore, the present study aimed to investigate the predictor of SCI after transfemoral (TF)-TAVR. Methods: We enrolled 58 consecutive patients (median age: 84 y.o (quartile 80-86), and 34.5% male)), who underwent TF-TAVR and performed DW-MRI within 10 days after procedure, between January 2016 and March 2017. We examined the incidence of SCI, and counted high-intensity spot (HIS) at DW-MRI in all patients. Subsequently, we evaluated the predictor of SCI using logistic regression analysis. As confounders, we selected Society of Thoracic Surgeon score (STS), calcium vol...
Abstract 10195: 20-Hour Preprocedural Hydration is Not Superior to 5-Hour Preprocedural Hydration in the Prevention of Contrast-Induced Increases in Serum Creatinine and Cystatin C in Patients with Renal Insufficiency
Authors: Kumie Torigoe, Akira Tamura, Toru Watanabe, Junichi Kadota
Journal: Circulation (2011)

Background: Although intravenous hydration with isotonic saline is the standard therapy for the prevention of contrast-induced nephropathy (CIN), there is still insufficient evidence concerning the optimal time to initiate preprocedural hydration with intravenous isotonic saline. Methods: This study prospectively compared the contrast-induced increases in serum creatinine and cystatin C between 5-hour preprocedural intravenous hydration with isotonic saline (5h-HS) and 20-hour preprocedural intravenous hydration with isotonic saline (20h-HS) in 122 patients with renal insufficiency (estimated glomerular filtration rate of 15 - 60 ml/min/1.73 m2) undergoing an elective coronary procedure. The patients were randomly assigned to receive either 5h-HS (n = 60) or 20h-HS (n = 62). Serum creatinine and cystatin C were measured at baseline, immediately before contrast exposure, and 24 hours and 48 hours after contrast exposure. The primary end points were the maximal absolute and % changes in serum creatinine and...
AB1081 First transition clinic of adolescents with rheumatic diseases in mÉxico, a pilot study
Authors: N.E. Rubio-Pérez, A.C. Arana-Guajardo, F. García-Rodríguez, A.V. Villarreal-Treviño, M.D. Torres-Made, J.A. López-Rangel, O. Salas-Fraire, P. Ancer-Rodríguez, M.E. Corral-Trujillo, D.A. Galarza-Delgado
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The adolescence is a critical period when different process are made, as identity, cognitive changes, anhance of autonomy, etc. Besides that, an adolescent with rheumatic disease has to front facing the disease acceptance. Alrealy, different Transition Programs are made around the world. In México does not exist this important project yet. <h3>Objectives</h3> Provide and uninterrumped, multi-disciplinary and coordinated, properly developed health system with a comprehensive and psychosocial background. <h3>Methods</h3> We included rheumatologist, rehabilitation specialists, psychiatrist, nutritionist, clinical psychologist, nurse and social services. Got Transition Questionnaire (GOT) in Spanish version was used to evaluated patients and parents to evaluated the knowledge in transition process. We implemented the beginning of the clinic last July. We included patients with established rheumatic diseases, older than 16 years old. We use descriptive statistics wit measures of central tendency or frequencies depending on variable characteristics. We use Spearman's correlation test to evaluated concordance of answers in GOT between parents and patients. <h3>Results</h3> We made a systematic evaluation program of all patients. Nineteen patients had already seenat the ciinic, most of them are female, the rest of clinical variables are shown in Table 1. Even though we found a positive Spearman's coefficient (rho), and significant difference in answers related with "Perception of capability of adult-centred health care", "Health knowledge", and "Use of health-care services knowledge", GOT results demonstrate weak of correlation between answers from patients and their parents. Correlation plots from GOT results are shown in figure 1. <h3>Conclusions</h3> In this pilot study, we shown a high prevalence of psychiatric, nutritional, and mobility problems among adolescents, adding the non-concordance of transtion abilities percepcion in GOT answers between parents and patients. These results encourage the need of an organised, specialised, multidisciplinary, and integrated clinic in which the patient could adapt to adult care centres. <h3>Reference</h3> [1] Oen K. Curr Opini Rheumatol 2000;12;410–4. http://www.gottransition.org/ <h3>Acknowledgements</h3> Elisa M. Garcia Alfaro. Liliana P. Barbosa Garza <h3>Disclosure of Interest</h3> None declared
Sepsis associated acute kidney injury
Authors: Jason T Poston, Jay L Koyner
Journal: BMJ (2019)

ABSTRACT Sepsis is defined as organ dysfunction resulting from the host’s deleterious response to infection. One of the most common organs affected is the kidneys, resulting in sepsis associated acute kidney injury (SA-AKI) that contributes to the morbidity and mortality of sepsis. A growing body of knowledge has illuminated the clinical risk factors, pathobiology, response to treatment, and elements of renal recovery that have advanced our ability to prevent, detect, and treat SA-AKI. Despite these advances, SA-AKI remains an important concern and clinical burden, and further study is needed to reduce the acute and chronic consequences. This review summarizes the relevant evidence, with a focus on the risk factors, early recognition and diagnosis, treatment, and long term consequences of SA-AKI. In addition to literature pertaining to SA-AKI specifically, pertinent sepsis and acute kidney injury literature relevant to SA-AKI was included.
Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)
Authors: Nadia Jaekel, Karolin Hubert, Rainer Krahl, M Haenel, Georg Maschmeyer, Regina Herbst, Christian Jakob, Susann Schulze, Song-Yau Wang, Michael Cross, Christoph Kahl, Maxi Wass, Herbert G. Sayer, Oana Brosteanu, Dietger Niederwieser, Haifa Kathrin Al-Ali
Journal: Blood (2017)